Comparative Pharmacology
Head-to-head clinical analysis: PRILOSEC OTC versus PROTONIX IV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRILOSEC OTC versus PROTONIX IV.
PRILOSEC OTC vs PROTONIX IV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme (proton pump) in gastric parietal cells, suppressing gastric acid secretion.
Pantoprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells.
20 mg orally once daily for 14 days for frequent heartburn; may repeat 14-day course every 4 months.
40 mg intravenously once daily for 7-10 days; for pathological hypersecretory conditions, initial dose 80 mg IV every 12 hours, titrate per acid output.
None Documented
None Documented
Approximately 0.5–1 hour in healthy subjects; longer (up to 3 hours) in slow metabolizers or hepatic impairment. Clinically, the duration of acid suppression exceeds the half-life due to accumulation in parietal cell canaliculi.
1-2 hours in healthy subjects; prolonged to 3.5-8 hours in hepatic impairment.
Primarily hepatic metabolism; about 80% of metabolites are excreted in urine, and the remainder in feces via bile. Less than 1% of unchanged drug is excreted in urine.
Primarily hepatic metabolism; 71-82% of dose excreted in urine as metabolites, 18-20% in feces.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor